Navigation Links
ImmBio Wins Funding from UK Government-Backed Biomedical Catalyst to Develop Multi-Strain Pneumococcal Vaccine

CAMBRIDGE, England, March 12, 2013 /PRNewswire/ --

ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately £0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax™, which targets a wide range of strains of the bacteria.  This new grant follows the award of approximately £1 million ($1.5 million) at the end of 2012 by the Biomedical Catalyst, to support the development of ImmBio's novel meningococcal B vaccine, MenBioVax™.  The Biomedical Catalyst is a programme of public funding managed jointly by the UK's innovation agency, the Technology Strategy Board, and the Medical Research Council, which has to date awarded nearly £96 million to 115 projects to support the accelerated development of innovative solutions to healthcare challenges.

ImmBio's vaccine candidates are based on its proprietary ImmBioVax™ technology platform.  This uses novel cell-culture production processes to stress the target bacterial pathogen, mimicking the natural immune response to infection.  This innovative approach generates vaccines that incorporate multi-protein complexes, offering potential broad-based protection against a wide range of pathogen strains without the need for adjuvants or other immune stimulators.  

"ImmBio is delighted to receive funding from the UK's innovation agency and Medical Research Council to progress the development of our novel vaccines", said Graham Clarke , CEO of ImmBio.  "Successfully winning funding in both the first and second Biomedical Catalyst investment rounds represents a major vote of confidence in our ImmBioVax™ vaccine technology.  This most recent award recognises the need for effective new vaccines against invasive pneumococcal disease, and the potential of our technology to protect against a wide range of disease-causing strains."

About pneumococcal disease

Invasive pneumococcal disease is caused by Streptococcus pneumoniae bacteria.  The infection can be devastating, particuarly in developing countries, and is responsible for greater infant mortality than tuberculosis, HIV and malaria combined.  Between 5-10% of adults and 20-40% of children carry the bacteria, and over 90 different strains have been identified to date.  These evolve continually leading to the emergence of new strains, and antibiotic resistance is a significant and growing problem.  Current vaccines cover only a limited number of existing strains and may not be effective against those that emerge in future.  In addition, existing vaccines can be expensive for routine use in developing countries.

About ImmBio

ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary novel ImmBioVax™ technology.  During vaccine production, ImmBioVax™ mimics the normal immune response to a pathogen.  This process produces vaccines containing multi-protein complexes that are designed to elicit broad-based priming of the immune system to block subsequent infection by multiple strains of the pathogen.  ImmBio is developing vaccines against a number of diseases, including invasive meningococcal disease, tuberculosis and invasive pneumococcal disease.

About the Biomedical Catalyst

The Biomedical Catalyst, announced by Prime Minister David Cameron in December 2011, is a programme of public funding designed to deliver growth to the UK life sciences sector.  Delivered jointly by the Medical Research Council and the Technology Strategy Board, the Biomedical Catalyst provides responsive and effective support for the best life science opportunities arising in the UK.  The programme is open to UK academics and SMEs and seeks to support those opportunities that demonstrate the highest scientific and commercial potential, irrespective of medical area.  For further information please visit:

Graham Clarke
Tel: +44(0)1223-496117

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Independa Closes Convertible Note Funding at $2.35 Million
2. Xtelligent Media Raises $800K in Funding and Launches
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Igenica Closes $33 Million in Series C Funding
5. Elsevier and Russias Skolkovo Foundation Sign Access Agreement to SciVerse Scopus and SciVal Funding
6. BONESUPPORT Closes Second Tranche of Funding
7. DePuy & Transvaginal Mesh Lawsuit Settlement Funding Leads Legal-Bay to Banner 2nd Quarter
8. RD Legal Funding Provides Immediate Settlement Financing to Growing Number of Yaz and Yasmin Plaintiffs
9. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
10. Prosum Kicks Off Crowd Funding for Cancer Research
11. Healthcare Expense Management Leader Patientco Receives $3.75M in funding led by BlueCross BlueShield Venture Partners and Sandbox Industries
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):